Signal Advisors Wealth LLC Acquires 5,876 Shares of Merck & Co., Inc. $MRK

Posted by Brenda Bartman on Jun 24th, 2026

Signal Advisors Wealth LLC boosted its holdings in Merck & Co., Inc. (NYSE:MRK – Free Report) by 142.3% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,005 shares of the company’s stock after acquiring an additional 5,876 shares during the quarter. Signal Advisors Wealth LLC’s holdings in Merck & Co., Inc. were worth $1,203,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of MRK. D.A. Davidson & CO. increased its stake in shares of Merck & Co., Inc. by 4.4% during the fourth quarter. D.A. Davidson & CO. now owns 576,959 shares of the company’s stock valued at $60,731,000 after buying an additional 24,576 shares during the period. Farther Finance Advisors LLC increased its position in Merck & Co., Inc. by 48.9% during the 4th quarter. Farther Finance Advisors LLC now owns 97,818 shares of the company’s stock valued at $10,296,000 after purchasing an additional 32,114 shares during the period. Coldstream Capital Management Inc. increased its position in Merck & Co., Inc. by 12.7% during the 3rd quarter. Coldstream Capital Management Inc. now owns 123,366 shares of the company’s stock valued at $10,364,000 after purchasing an additional 13,940 shares during the period. Campbell Capital Management Inc. bought a new position in Merck & Co., Inc. in the 3rd quarter worth $1,866,000. Finally, Norris Perne & French LLP MI lifted its position in shares of Merck & Co., Inc. by 12.8% in the 4th quarter. Norris Perne & French LLP MI now owns 252,162 shares of the company’s stock worth $26,543,000 after purchasing an additional 28,635 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Citigroup assumed coverage on shares of Merck & Co., Inc. in a research report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price target on the stock. Wall Street Zen upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday, June 6th. JPMorgan Chase & Co. increased their target price on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research report on Monday, April 6th. Zacks Research upgraded Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 17th. Finally, UBS Group increased their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, April 13th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and a consensus price target of $128.18.

Check Out Our Latest Analysis on MRK

Merck & Co., Inc. Price Performance

MRK stock opened at $119.71 on Wednesday. The firm has a 50 day moving average price of $115.76 and a 200-day moving average price of $113.91. Merck & Co., Inc. has a 52-week low of $76.66 and a 52-week high of $125.14. The firm has a market capitalization of $295.66 billion, a price-to-earnings ratio of 33.72, a PEG ratio of 2.60 and a beta of 0.21. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm had revenue of $16.29 billion for the quarter, compared to analysts’ expectations of $15.85 billion. During the same period in the previous year, the firm posted $2.22 EPS. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities research analysts forecast that Merck & Co., Inc. will post 5.17 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be given a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, June 15th. Merck & Co., Inc.’s payout ratio is currently 95.77%.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

Positive Sentiment: Merck said tulisokibart met its primary and key secondary endpoints in the Phase 3 ATLAS-UC induction study for moderately to severely active ulcerative colitis, strengthening confidence in a potentially important new immunology asset. Merck’s Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study
Positive Sentiment: The tulisokibart result adds to Merck’s recent pipeline momentum and gives investors another potential growth driver as the company looks to diversify sales away from Keytruda over time. Merck’s bowel disease drug meets main goal in late-stage trial
Positive Sentiment: Merck also recently won FDA expansion approvals for KEYTRUDA/KEYTRUDA QLEX with WELIREG in kidney cancer and for CAPVAXIVE in higher-risk children and adolescents, reinforcing near-term commercial strength across multiple franchises. Merck (MRK) Wins FDA Expansions, Posts HIV Data, And Ends Lung Cancer Trial

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.